# EDGAR Filing Document

**Accession Number:** 0001751912
**File Stem:** 0001104659-26-015192
**Filing Date:** 2026-2
**Character Count:** 3996
**Document Hash:** 279ec10824b8c0bedf1f16f11d2c1471
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-015192.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001104659-26-015192

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260213

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NERVGEN PHARMA CORP.
- **CENTRAL INDEX KEY:** 0001751912
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43048
- **FILM NUMBER:** 26632659

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 1703 - 595 BURRARD STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V7X 1J1
- **BUSINESS PHONE:** 6047225361

**MAIL ADDRESS:**
- **STREET 1:** SUITE 1703 - 595 BURRARD STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V7X 1J1

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE<br> SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

Commission File Number: **001-43048**

**NERVGEN PHARMA CORP.**

(Exact name of Registrant as specified in its charter)

**N/A**<br> (Translation of Registrant's name)

**112-970 Burrard Street, Unit 1290<br> Vancouver, British Columbia, Canada V6Z 2R4<br> Telephone: (778) 731-1711**<br> (Address and telephone number of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ◻ Form 40-F ⌧

**EXPLANATORY NOTE**

**Chief Financial Officer Resignation and Appointment**

On February 12, 2026, NervGen Pharma Corp. (the "Company") announced that William J. Adams tendered his resignation as the Chief Financial Officer and Secretary and Principal Financial and Accounting Officer of the Company, due to his retirement. Mr. Adams' resignation is effective as of March 15, 2026 (the "Effective Date"). Mr. Adams' resignation was not the result of any disagreements with the Company, its management or the Company's Board of Directors (the "Board").

Mr. Adams will be providing transitional services through June 15, 2026. In connection with these transitional services, Mr. Adams will receive one-third of his current base salary. Mr. Adams will also be entitled to receive an extension of the expiration date of his vested stock awards as set forth under his equity award agreements.

On February 12, 2026, the Board approved the appointment of Dr. Adam Rogers as the Company's interim Chief Financial Officer and the Company's Principal Financial and Accounting Officer, effective as of the Effective Date.

Dr. Rogers' biography is incorporated by reference from the Company's Report of Foreign Issuer on Form 6-K (File No. 001-43048) filed with the Securities and Exchange Commission on February 10, 2026.

**INCORPORATION BY REFERENCE**

This Report on Form 6-K, including the exhibits hereto, shall be deemed to be incorporated by reference into the registrant's Registration Statement on [Form F-10 (File No. 333-292197)](https://www.sec.gov/Archives/edgar/data/1751912/000110465925122026/tm2532520-1_f10.htm), to be a part thereof from the date on which this Report on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **<br> NERVGEN PHARMA CORP.** | **<br> NERVGEN PHARMA CORP.** |
| Date: February 13, 2026 | By: | /s/ Adam Rogers |
|  |  | Name: Adam Rogers |
|  |  | Title: Chief Executive Officer |

---